Biological markers in inflammatory rheumatic diseases

Area of Science:

• Rheumatology and Immunology
• Biomarker Discovery
• Molecular Pathology

Background:

• Biological markers are crucial for diagnosing and monitoring inflammatory rheumatisms and connective tissue diseases.
• Current markers like C-reactive protein (CRP) are not entirely specific and may not accurately reflect long-term disease progression.
• Serum amyloid A (SAA) and various antinuclear antibodies (e.g., anti-ds DNA) offer insights into disease activity and pathogenesis, particularly in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Purpose of the Study:

• To review the utility of biological markers in diagnosing and monitoring inflammatory rheumatisms and connective tissue diseases.
• To highlight the roles of C-reactive protein (CRP), Serum amyloid A (SAA), and antinuclear antibodies (ANA) in disease activity and prognosis.
• To explore the evolving understanding of anti-DNA antibody production in relation to DNA-protein complexes.

Main Methods:

• Literature review of established and emerging biological markers for inflammatory and autoimmune diseases.
• Analysis of the correlation between marker levels and disease activity in conditions like RA and SLE.
• Discussion of the immunological basis for antibody production against cellular components.

Main Results:

• C-reactive protein (CRP) and Serum amyloid A (SAA) are sensitive acute phase reactants used in monitoring RA, with SAA potentially being more sensitive than CRP.
• Antinuclear antibodies, particularly anti-ds DNA antibodies in SLE, correlate with disease activity.
• Antibody production may be a response to DNA-protein complexes, including histones and ribonucleoproteins, with implications for disease subset definition and prognosis.

Conclusions:

• Biological markers significantly aid in the diagnosis and management of inflammatory and connective tissue diseases.
• Understanding the specificity and correlation of markers like CRP, SAA, and various autoantibodies is key to effective patient monitoring.
• Ongoing research into antibodies targeting DNA-protein complexes promises further refinement in defining disease subsets and predicting outcomes in rheumatological conditions.